TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease

Paramita Chakrabarty, Andrew Li, Thomas B. Ladd, Michael R. Strickland, Emily J. Koller, Jeremy D. Burgess, Cory C. Funk, Pedro E. Cruz, Mariet Allen, Mariya Yaroshenko, Xue Wang, Curtis Younkin, Joseph Reddy, Benjamin Lohrer, Leonie Mehrke, Brenda D. Moore, Xuefei Liu, Carolina Ceballos‑Diaz, Awilda M. Rosario, Christopher MedwayChristopher Janus, Hong Dong Li, Dennis W Dickson, Benoit I. Giasson, Nathan D. Price, Steven G Younkin, Nilufer Taner, Todd E. Golde

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There is considerable interest in harnessing innate immunity to treat Alzheimer's disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor-based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.

Original languageEnglish (US)
Pages (from-to)2247-2264
Number of pages18
JournalJournal of Experimental Medicine
Volume215
Issue number9
DOIs
StatePublished - Jan 1 2018

Fingerprint

Toll-Like Receptor 5
Amyloid
Alzheimer Disease
Therapeutics
Flagellin
Biological Therapy
Gene Expression Profiling
Biological Products
Innate Immunity
Immunoglobulin G
Pathology
Gene Expression
Proteins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., ... Golde, T. E. (2018). TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. Journal of Experimental Medicine, 215(9), 2247-2264. https://doi.org/10.1084/jem.20180484

TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. / Chakrabarty, Paramita; Li, Andrew; Ladd, Thomas B.; Strickland, Michael R.; Koller, Emily J.; Burgess, Jeremy D.; Funk, Cory C.; Cruz, Pedro E.; Allen, Mariet; Yaroshenko, Mariya; Wang, Xue; Younkin, Curtis; Reddy, Joseph; Lohrer, Benjamin; Mehrke, Leonie; Moore, Brenda D.; Liu, Xuefei; Ceballos‑Diaz, Carolina; Rosario, Awilda M.; Medway, Christopher; Janus, Christopher; Li, Hong Dong; Dickson, Dennis W; Giasson, Benoit I.; Price, Nathan D.; Younkin, Steven G; Taner, Nilufer; Golde, Todd E.

In: Journal of Experimental Medicine, Vol. 215, No. 9, 01.01.2018, p. 2247-2264.

Research output: Contribution to journalArticle

Chakrabarty, P, Li, A, Ladd, TB, Strickland, MR, Koller, EJ, Burgess, JD, Funk, CC, Cruz, PE, Allen, M, Yaroshenko, M, Wang, X, Younkin, C, Reddy, J, Lohrer, B, Mehrke, L, Moore, BD, Liu, X, Ceballos‑Diaz, C, Rosario, AM, Medway, C, Janus, C, Li, HD, Dickson, DW, Giasson, BI, Price, ND, Younkin, SG, Taner, N & Golde, TE 2018, 'TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease', Journal of Experimental Medicine, vol. 215, no. 9, pp. 2247-2264. https://doi.org/10.1084/jem.20180484
Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD et al. TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. Journal of Experimental Medicine. 2018 Jan 1;215(9):2247-2264. https://doi.org/10.1084/jem.20180484
Chakrabarty, Paramita ; Li, Andrew ; Ladd, Thomas B. ; Strickland, Michael R. ; Koller, Emily J. ; Burgess, Jeremy D. ; Funk, Cory C. ; Cruz, Pedro E. ; Allen, Mariet ; Yaroshenko, Mariya ; Wang, Xue ; Younkin, Curtis ; Reddy, Joseph ; Lohrer, Benjamin ; Mehrke, Leonie ; Moore, Brenda D. ; Liu, Xuefei ; Ceballos‑Diaz, Carolina ; Rosario, Awilda M. ; Medway, Christopher ; Janus, Christopher ; Li, Hong Dong ; Dickson, Dennis W ; Giasson, Benoit I. ; Price, Nathan D. ; Younkin, Steven G ; Taner, Nilufer ; Golde, Todd E. / TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. In: Journal of Experimental Medicine. 2018 ; Vol. 215, No. 9. pp. 2247-2264.
@article{dde8ff88d9f24a2d86c70e203aea997f,
title = "TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease",
abstract = "There is considerable interest in harnessing innate immunity to treat Alzheimer's disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor-based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.",
author = "Paramita Chakrabarty and Andrew Li and Ladd, {Thomas B.} and Strickland, {Michael R.} and Koller, {Emily J.} and Burgess, {Jeremy D.} and Funk, {Cory C.} and Cruz, {Pedro E.} and Mariet Allen and Mariya Yaroshenko and Xue Wang and Curtis Younkin and Joseph Reddy and Benjamin Lohrer and Leonie Mehrke and Moore, {Brenda D.} and Xuefei Liu and Carolina Ceballos‑Diaz and Rosario, {Awilda M.} and Christopher Medway and Christopher Janus and Li, {Hong Dong} and Dickson, {Dennis W} and Giasson, {Benoit I.} and Price, {Nathan D.} and Younkin, {Steven G} and Nilufer Taner and Golde, {Todd E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1084/jem.20180484",
language = "English (US)",
volume = "215",
pages = "2247--2264",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "9",

}

TY - JOUR

T1 - TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease

AU - Chakrabarty, Paramita

AU - Li, Andrew

AU - Ladd, Thomas B.

AU - Strickland, Michael R.

AU - Koller, Emily J.

AU - Burgess, Jeremy D.

AU - Funk, Cory C.

AU - Cruz, Pedro E.

AU - Allen, Mariet

AU - Yaroshenko, Mariya

AU - Wang, Xue

AU - Younkin, Curtis

AU - Reddy, Joseph

AU - Lohrer, Benjamin

AU - Mehrke, Leonie

AU - Moore, Brenda D.

AU - Liu, Xuefei

AU - Ceballos‑Diaz, Carolina

AU - Rosario, Awilda M.

AU - Medway, Christopher

AU - Janus, Christopher

AU - Li, Hong Dong

AU - Dickson, Dennis W

AU - Giasson, Benoit I.

AU - Price, Nathan D.

AU - Younkin, Steven G

AU - Taner, Nilufer

AU - Golde, Todd E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - There is considerable interest in harnessing innate immunity to treat Alzheimer's disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor-based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.

AB - There is considerable interest in harnessing innate immunity to treat Alzheimer's disease (AD). Here, we explore whether a decoy receptor strategy using the ectodomain of select TLRs has therapeutic potential in AD. AAV-mediated expression of human TLR5 ectodomain (sTLR5) alone or fused to human IgG4 Fc (sTLR5Fc) results in robust attenuation of amyloid β (Aβ) accumulation in a mouse model of Alzheimer-type Aβ pathology. sTLR5Fc binds to oligomeric and fibrillar Aβ with high affinity, forms complexes with Aβ, and blocks Aβ toxicity. Oligomeric and fibrillar Aβ modulates flagellin-mediated activation of human TLR5 but does not, by itself, activate TLR5 signaling. Genetic analysis shows that rare protein coding variants in human TLR5 may be associated with a reduced risk of AD. Further, transcriptome analysis shows altered TLR gene expression in human AD. Collectively, our data suggest that TLR5 decoy receptor-based biologics represent a novel and safe Aβ-selective class of biotherapy in AD.

UR - http://www.scopus.com/inward/record.url?scp=85055880011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055880011&partnerID=8YFLogxK

U2 - 10.1084/jem.20180484

DO - 10.1084/jem.20180484

M3 - Article

C2 - 30158114

AN - SCOPUS:85055880011

VL - 215

SP - 2247

EP - 2264

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 9

ER -